<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898117</url>
  </required_header>
  <id_info>
    <org_study_id>M13TNB</org_study_id>
    <secondary_id>2013-001484-23</secondary_id>
    <secondary_id>NL44403.031.13</secondary_id>
    <nct_id>NCT01898117</nct_id>
  </id_info>
  <brief_title>Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer</brief_title>
  <acronym>Triple-B</acronym>
  <official_title>Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor
      survival. TNBC can be divided into at least two molecular entities; BRCA-like and
      non-BRCA-like. In this trial we would like to investigate whether a molecular subgroup exists
      within TNBCs that derives a benefit from atezolizumab added to first line chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atezolizumab, a humanized monoclonal antibody that targets human programmed deathâˆ’ligand 1
      (PD-L1) has shown activity in TNBC. Early clinical trials with anti-PD-(L)1 monotherapy have
      shown that the median duration to response in TNBC is remarkably long (18 weeks) compared to
      cytotoxic chemotherapy. Since advanced TNBC is characterized by rapid disease progression,
      most patients with TNBC may not have the opportunity to derive benefit from immunotherapy. We
      hypothesize that by combining atezolizumab with paclitaxel or carboplatin-cyclophosphamide
      the desired rapid tumor control will be obtained with chemotherapy and subsequently
      atezolizumab can result in durable responses in a significant subset of patients. It is
      unknown whether addition of atezolizumab to first line chemotherapy in TNBC is more
      beneficial than adding this antibody to a second line treatment schedule. Because of this and
      because of the poor outcome of patients with advanced TNBC experiencing disease progression
      after first line palliative chemotherapy, patients who were randomized to a chemotherapy only
      arm in this study will be offered the opportunity to cross over to the other chemotherapy
      regimen plus atezolizumab at disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validate the BRCA-like test</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <description>Validate the BRCA-like test in predicting differential PFS with first line alkylating and platinum agents when compared to paclitaxel in TNBC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of objective response by adding atezolizumab</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <description>Determine whether atezolizumab added to first line palliative chemotherapy improves objective response in TNBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define predictive biomarkers for objective response gain</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months</time_frame>
    <description>Define predictive biomarkers for objective response gain of the addition of atezolizumab to first line chemotherapy; e.g PD-L1, intratumoral CD8, TILs and pre-treatment LDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define predictive biomarkers for PFS gain</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months</time_frame>
    <description>Define predictive biomarkers for PFS gain of carboplatin-cyclophosphamide or paclitaxel chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine PFS in BRCA like TNBC</measure>
    <time_frame>From date of randomization until date of first documented progression or date of death, which ever comes first, assessed up to 120 months</time_frame>
    <description>Determine whether an alkylating platinum regimen is more effective then paclitaxel regarding PFS in BRCA like TNBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine PFS in non BRCA like TNBC</measure>
    <time_frame>From date of randomization until date of first documented progression or date of death, which ever comes first, assessed up to 120 months</time_frame>
    <description>Determine whether paclitaxel is more effective then an alkylating platinum regimen regarding PFS in non BRCA like TNBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <description>Evaluation of overall survival (OS) for all (sub)group comparisons as pre-specified for PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of all study regimens</measure>
    <time_frame>Assessed at 1 year</time_frame>
    <description>Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine PFS in cross over</measure>
    <time_frame>At 6 and 12 months and up to 120 months</time_frame>
    <description>Determine the PFS and objective response after cross over to the other chemotherapy regimen with atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine PFS in TNBC molecular subtypes</measure>
    <time_frame>Assessed up to 120 months</time_frame>
    <description>Determine whether TNBC molecular subtypes as defined by gene expression are predictive for differential PFS benefit of atezolizumab added to first line chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Carbo/cyclo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbo/cyclo + Atezolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel + atezolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbo/cyclo</intervention_name>
    <arm_group_label>Carbo/cyclo</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbo/cyclo + atezolizumab</intervention_name>
    <arm_group_label>Carbo/cyclo + Atezolizumab</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Atezolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Atezolizumab</intervention_name>
    <arm_group_label>Paclitaxel + atezolizumab</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>Atezolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastasized or locally advanced incurable triple negative breast cancer; patients
             with stage IV at diagnosis are eligible as well. If the primary lesion is the only
             measurable lesion according to RECIST criteria, every locoregional treatment must be
             mentioned to the investigators.

          -  Histologically confirmed triple negative breast cancer (ER: &lt; 10% nuclear staining of
             tumor cells on IHC; HER2: either score 0 or 1 at immunohistochemistry or negative at
             in situ hybridization [CISH or FISH] in case of score 2 or 3 on IHC)

          -  Histological confirmation of triple negative breast cancer of a metastatic lesion is
             recommended

          -  Histological or cytological confirmation of metastatic breast cancer is required in
             case of normal CA 15.3 levels

          -  Primary tumor or metastasis tissue (10 x10 Î¼m blank slides FFPE tumor material) sent
             to NKI-AVL for BRCA-like testing

          -  Pretreatment histological biopsy of a metastatic lesion for the translational research
             questions (tumor tissue from bone metastases cannot be used).

          -  No previous cytotoxic therapy for metastatic disease

          -  Disease-free interval of at least 12 months after completion of adjuvant paclitaxel or
             platinum compound therapy

          -  Disease-free interval of at least 6 months after completion of adjuvant docetaxel

          -  Measurable disease according to RECIST v1.1

          -  WHO performance status of 0 or 1

          -  Adequate bone marrow function: neutrophils â‰¥ 1.5 x 10E9 cells/l, platelets â‰¥100 x 10E9
             cells/l, Hb â‰¥ 6.2 mmol/l.

          -  Normal liver function: bilirubin &lt; 1.5 x upper limit of the normal range (ULN);
             alkaline phosphatase &lt; 2.5 x ULN (&lt; 5 x ULN in case of liver metastases, and &lt; 7 x ULN
             in case of bone metastases); transaminases (ASAT/ALAT) &lt; 2.5 x ULN (and &lt; 5 x ULN in
             case of liver metastases).

          -  Normal renal function:

             &gt; calculated (Cockcroft-Gault) or measured creatinine clearance &gt; 50 mL/min

          -  INR &lt; 1.5 and APTT normal, unless patient is on stable anti-coagulant treatment for at
             least two weeks with a low molecular weight heparin or coumarin, then an INR within
             the target range (usually between 2 and 3) is allowed.

          -  Written informed consent

        Exclusion Criteria:

          -  Receptor conversion to hormone receptor positive (defined as &gt;= 10% positive ER or PgR
             tumor cells) or HER2 positive

          -  Another cancer except basal-cell carcinoma of the skin or in situ cervical cancer
             within the previous 5 years

          -  Other antitumor therapy within the previous 21 days

          -  Radiotherapy with palliative intent within the previous 7 days before randomization.

          -  Known CNS disease except for treated brain metastases.

          -  Uncontrolled serious medical or psychiatric illness

          -  Pre-existing peripheral neuropathy &gt; grade 1 (NCI-CTC AE (version 4.03)) at inclusion

          -  Severe infection within 4 weeks prior to randomization

          -  received antibiotocs within 2 weeks prior to cycle 1, day 1

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to randomization or anticipation of need for major surgical procedure during the
             course of the study

          -  New York Heart Association Class II or greater congestive heart failure. LVEF by MUGA,
             ultrasound or MRI must be â‰¥ 50% and should be performed within 4 weeks prior to
             randomization if cardiac failure is suspected.

          -  History of myocardial infarction or unstable angina within 6 months prior to
             randomization

          -  History of myocardial infarction or unstable angina or unstable arrhytmias within 3
             months prior to randomization

        futher criteria, see protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rianne Oosterkamp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MC Haaglanden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marleen Kok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine C Linn, Prof. MD</last_name>
    <phone>+3120512</phone>
    <phone_ext>2951</phone_ext>
    <email>s.linn@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid A. Mandjes, MSc</last_name>
    <phone>+3120512</phone>
    <phone_ext>2880</phone_ext>
    <email>i.mandjes@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MCA</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Vrijaldenhoven, MD</last_name>
    </contact>
    <investigator>
      <last_name>S Vrijaldenhoven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZGT</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BovenIJ</name>
      <address>
        <city>Amsterdam</city>
        <zip>1034 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S E Dohmen, MD</last_name>
      <email>s.dohmen@bovenij.nl</email>
    </contact>
    <investigator>
      <last_name>S E Dohmen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabine C Linn, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZVU</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I R Konings, MD</last_name>
      <email>m.konings@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>I R Konings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L Strobbe, MD</last_name>
    </contact>
    <investigator>
      <last_name>L Strobbe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lievensberg ziekenhuis</name>
      <address>
        <city>Bergen op Zoom</city>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M M Troost, MD</last_name>
      <email>M.Troost@lievensberg.nl</email>
    </contact>
    <investigator>
      <last_name>M M Troost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <zip>1940 EB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R C Rietbroek, MD</last_name>
      <email>rrietbroek@rkz.nl</email>
    </contact>
    <investigator>
      <last_name>R C Rietbroek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IJsselland ziekenhuis</name>
      <address>
        <city>Capelle Aan Den IJssel</city>
        <zip>2906 ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D F Kehrer, MD</last_name>
    </contact>
    <investigator>
      <last_name>D F Kehrer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haga</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deventer ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A L Imholz, MD</last_name>
      <email>imholza@dz.nl</email>
    </contact>
    <investigator>
      <last_name>A L Imholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nijsmellinghe</name>
      <address>
        <city>Drachten</city>
        <zip>9202 NN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Hovenga, MD</last_name>
      <email>s.hovenga@nijsmellinghe.nl</email>
    </contact>
    <investigator>
      <last_name>S Hovenga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A W Haringhuizen, MD</last_name>
      <email>haringhuizena@zgv.nl</email>
    </contact>
    <investigator>
      <last_name>A W Haringhuizen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M W Dercksen, MD</last_name>
    </contact>
    <investigator>
      <last_name>M W Dercksen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter ziekenhuis</name>
      <address>
        <city>Goes</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H van Halteren, MD</last_name>
    </contact>
    <investigator>
      <last_name>H van Halteren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B C Tanis, MD</last_name>
      <email>bea.tanis@ghz.nl</email>
    </contact>
    <investigator>
      <last_name>B C Tanis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Temizkan, MD</last_name>
    </contact>
    <investigator>
      <last_name>M Temizkan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B de Valk, MD</last_name>
      <email>bdevalk@spaarneziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B de Valk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCL</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H de Graaf, MD</last_name>
      <email>graafhi@znb.nl</email>
    </contact>
    <investigator>
      <last_name>H de Graaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J R Kroep, MD</last_name>
      <email>j.r.kroep@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>J R Kroep, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCH</name>
      <address>
        <city>Leidschendam</city>
        <zip>2262 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H M Oosterkamp, MD</last_name>
      <email>h.oosterkamp@mchaaglanden.nl</email>
    </contact>
    <investigator>
      <last_name>H M Oosterkamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Fransicus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A P Hamberg, MD</last_name>
      <email>p.hamberg@sfg.nl</email>
    </contact>
    <investigator>
      <last_name>A P Hamberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ikazia</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>F E de Jong, MD</last_name>
      <email>fe.de.jongh@ikazia.nl</email>
    </contact>
    <investigator>
      <last_name>F E de Jong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vlietland ziekenhuis</name>
      <address>
        <city>Schiedam</city>
        <zip>3118 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Q C van Rossum-Schornagel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Q C van Rossum-Schornagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J M van Riel, MD</last_name>
      <email>jmgriel@elisabeth.nl</email>
    </contact>
    <investigator>
      <last_name>J M van Riel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tweesteden ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>van Alphen, MD</last_name>
    </contact>
    <investigator>
      <last_name>van Alphen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum voor Noord-Limburg</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. J. van der Wouw, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>A. J. van der Wouw, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A H. Honkoop, MD</last_name>
      <email>a.h.honkoop@isala.nl</email>
    </contact>
    <investigator>
      <last_name>A H Honkoop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

